Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. mflodx

mfloDx SIGNED

Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mfloDx project word cloud

Explore the words cloud of the mfloDx project. It provides you a very rough idea of what is the project "mfloDx" about.

tuberculosis    thereby    rate    reduce    suffering    inappropriate    urgently    euros    flourishing    recommended    commercial    2000    point    infects    first    2030    tests    frac14    treat    projected    appropriate    life    treatment    tens    92    undergo    2024    care    faulty    resistant    times    patients    antibiotic    15    diagnoses    time    specificity    months    treatments    generation    lag    killed    bacteria    unnecessary    diagnostic    100    regimens    strains    detection    mid    platform    costly    grow    prescription    rapid    prevent    2015    untreatable    pilot    six    patient    organization    96    countries    showed    mflodx    curtail    market    close    33    income    tools    32k    suggest    incomplete    spreading    spread    forms    million    diagnostics    worldwide    accurate    diagnosis    billion    tb    people    stop    mdr    alarming    addressable    afflicted    power    infections    population    efficiency    thousands    world    health    recommend    drug    antibiotics    trained    global    983    minimdr    expenditure    tbplus    molecular    identification    prescriptions    incorrect    estimates    hours   

Project "mfloDx" data sheet

The following table provides information about the project.

Coordinator		 EMPE DIAGNOSTICS AB 

Organization address
address: KAROLINSKA ISTITUTE SCIENCE PARK NOBELS VAG 16
city: STOCKHOLM
postcode: 171 65
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMPE DIAGNOSTICS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

Tuberculosis (TB) killed 33 million people worldwide in 2000-2015 and infects an estimated ¼ of the world population. Drug-resistant forms of TB are flourishing at an alarming rate due to faulty diagnosis and widespread prescription of incorrect antibiotics. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of untreatable TB forms. Simple, low cost diagnostic tools are needed to enable point-of-care testing in low- and mid-income countries. mfloDx is a low-cost, simple diagnostic platform that can identify close to 100% of drug resistant TB cases. Pilot tests of the first product, miniMDR-TB, showed the efficiency and specificity to be 92-96% in agreement with that of another molecular test recommended by the World Health Organization. Our next-generation mfloDx products, MDR-TB and MDR-TBplus, are expected to have close to 100% MDR-TB identification power. The low cost of mfloDx tests will enable market uptake in highly afflicted developing countries, and thereby help to stop the loss of life, the spread of antibiotic-resistant infections, and prevent unnecessary costs. Projected global expenditure on diagnosis and treatment of TB will reach €983 billion between 2015-2030. The addressable market for TB diagnostics is projected to grow to €3.1 billion by 2024. Available commercial diagnostics for MDR-TB often deliver incomplete diagnoses and require long lag times, costly equipment (€15-32K), and highly trained personnel to recommend prescriptions. As a result, less than one-third of new TB patients undergo testing to determine appropriate antibiotic treatments. Our estimates suggest that mfloDx would reduce the treatment costs per MDR-TB patient by tens of thousands of euros and diagnosis time from about six months to two hours. This would avoid costly and inappropriate antibiotic regimens, reduce patient suffering, and curtail the spread of drug-resistant bacteria.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MFLODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MFLODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More